HFM
BBIO icon

Harvest Fund Management’s BridgeBio Pharma BBIO Stock Holding History

Harvest Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66K Sell
892
-46
-5% -$3.22K ﹤0.01% 319
2026
Q1 		$70K Sell
938
-3,038
-76% -$220K ﹤0.01% 324
2025
Q4 		$304K Buy
3,976
+3,321
+507% +$218K 0.01% 318
2025
Q3 		$34K Buy
+655
New +$31.9K ﹤0.01% 456

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Harvest Fund Management's BBIO Position: Q2 2026 in Review

Harvest Fund Management reduced its BridgeBio Pharma (BBIO) stake by 4.9% in Q2 2026, selling an estimated $3.22K and leaving 892 shares worth $66K. The position accounts for ﹤0.01% of the portfolio, ranked #319.

Harvest Fund Management first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $304K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Harvest Fund Management held 892 shares of BridgeBio Pharma worth $66K as of Q2 2026.
  • Harvest Fund Management sold 46 BridgeBio Pharma shares in Q2 2026, an estimated $3.22K.
  • BridgeBio Pharma made up ﹤0.01% of Harvest Fund Management's portfolio in Q2 2026, its #319 holding.
  • Harvest Fund Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Harvest Fund Management's BridgeBio Pharma position peaked at $304K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Harvest Fund Management's 13F filing for Q2 2026, filed 20 Aug 2026.